Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice for failing minimum stockholders' equity requirement, creating delisting risk.
Skye Bioscience receives Nasdaq delisting warning over equity shortfall
Filed May 15, 2026 · Period ending May 13, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Skye on May 13 that its stockholders' equity of $9.0M falls below the required $10M minimum for continued listing on the Global Market. Stock continues trading under SKYE during the compliance period.
Item 3.01 verify on EDGAR → -
high
Company has until June 29 to submit a compliance plan to Nasdaq. If accepted, Skye could receive up to 180 days (until November 9) to demonstrate it meets the equity requirement.
Item 3.01 verify on EDGAR → -
high
Management is evaluating options to regain compliance but explicitly states there is no assurance the company will successfully meet listing requirements or avoid delisting.
Item 3.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade SKYE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify